Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase-Reference-Cited by-同舟云学术

Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase

Published:2016-03 Issue:3 Volume:140 Page:457-462
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Grabowski Jacek P.,Harter Philipp,Heitz Florian,Pujade-Lauraine Eric,Reuss Alexander,Kristensen Gunnar,Ray-Coquard Isabelle,Heitz Julia,Traut Alexander,Pfisterer Jacobus,du Bois Andreas

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference34 articles.

1. Grading ovarian serous carcinoma using two-tier system;Malpica;Am. J. Surg. Pathol.,2004

2. Ovarian tumorigenesis. A proposed model based on morphological and molecular genetic analysis;Shih;Am. J. Pathol.,2004

3. A multistep model for ovarian tumorigenesis: the value of mutation analysis in the KRAS and BRAF genes;Russell;J. Pathol.,2004

4. Diverse tumorigenic pathways in ovarian serous carcinoma;Singer;Am. J. Pathol.,2002

5. Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma;Singer;Int. J. Gynecol. Pathol.,2003

Cited by 174 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. British Gynaecological Cancer Society (BGCS) ovarian, tubal and primary peritoneal cancer guidelines: Recommendations for practice update 2024;European Journal of Obstetrics & Gynecology and Reproductive Biology;2024-09

2. High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma;Gynecologic Oncology;2024-07

3. The survival benefit associated with complete macroscopic resection in epithelial ovarian cancer is histotype specific;JNCI Cancer Spectrum;2024-06-20

4. Targeted Therapies in Low-Grade Serous Ovarian Cancers;Current Treatment Options in Oncology;2024-06-13

5. Durable response to BRAF inhibitor monotherapy in recurrent metastatic low grade serous ovarian cancer;Gynecologic Oncology Reports;2024-06